Literature DB >> 30506332

Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia.

Daniele Roberto Giacobbe1,2, Alessio Signori3, Mario Tumbarello4, Riccardo Ungaro5,6, Giovanni Sarteschi5,6, Elisa Furfaro6, Malgorzata Mikulska5,6, Maurizio Sanguinetti7, Brunella Posteraro8, Angela Raffaella Losito4, Gennaro De Pascale9, Valerio Del Bono6,10, Claudio Viscoli5,6.   

Abstract

Desirability of outcome ranking (DOOR) has been developed for assessing desirability of outcome in interventional studies. However, its possible use in observational studies of the diagnosis and early treatment of infectious diseases has not been explored so far, and it might introduce interesting features in specific scenarios. This was a post hoc analysis of a prospective observational study in intensive care unit patients with sepsis and at risk of candidemia. The probabilities that a randomly selected patient would have a more, less, and equally cost-effective early therapeutic choice following a BDG-based diagnostic strategy rather than the empirical administration of antifungals to all patients were calculated using DOOR methods. The probability of a more cost-effective therapeutic choice following the BDG-based rather than the empirical strategy was 67.81% (95% CI 67.32-68.30), whereas the probabilities of a less and equally cost-effective early therapeutic choice were 19.68% (95% CI 19.27-20.10) and 12.50% (95% CI 12.16-12.85), respectively. The application of DOOR methods to observational studies focused on diagnosis and early treatment is a novel field that could merit further investigation.

Entities:  

Keywords:  Biomarker; Candidemia; DOOR; Diagnosis; Glucan

Mesh:

Substances:

Year:  2018        PMID: 30506332     DOI: 10.1007/s10096-018-3441-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  DOOR/RADAR: A Gateway Into the Unknown?

Authors:  Patrick Peter John Phillips; Tim Peter Morris; Ann Sarah Walker
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

2.  Reply to Phillips, Morris, and Walker.

Authors:  Scott Evans; Dean Follmann; David Schoenfeld; Vance G Fowler; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

3.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Authors:  Scott R Evans; Daniel Rubin; Dean Follmann; Gene Pennello; W Charles Huskins; John H Powers; David Schoenfeld; Christy Chuang-Stein; Sara E Cosgrove; Vance G Fowler; Ebbing Lautenbach; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

4.  (1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.

Authors:  Brunella Posteraro; Mario Tumbarello; Gennaro De Pascale; Elvira Liberto; Maria S Vallecoccia; Elena De Carolis; Valentina Di Gravio; Enrico M Trecarichi; Maurizio Sanguinetti; Massimo Antonelli
Journal:  J Antimicrob Chemother       Date:  2016-04-28       Impact factor: 5.790

5.  Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study.

Authors:  Cristóbal León; Sergio Ruiz-Santana; Pedro Saavedra; Beatriz Galván; Armando Blanco; Carmen Castro; Carina Balasini; Aránzazu Utande-Vázquez; Francisco J González de Molina; Miguel A Blasco-Navalproto; Maria J López; Pierre Emmanuel Charles; Estrella Martín; María Adela Hernández-Viera
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

6.  Novel Method Suggests Global Superiority of Short-Duration Antibiotics for Intra-abdominal Infections.

Authors:  Arthur R Celestin; Stephen R Odom; Konstantia Angelidou; Scott R Evans; Raul Coimbra; Christopher A Guidry; Joseph Cuschieri; Kaysie L Banton; Patrick J O'Neill; Reza Askari; Nicholas Namias; Therèse M Duane; Jeffrey A Claridge; E Patchen Dellinger; Robert A Sawyer; Charles H Cook
Journal:  Clin Infect Dis       Date:  2017-10-16       Impact factor: 9.079

  6 in total
  2 in total

1.  Impact of macrolide therapy in critically ill patients with acute respiratory failure: a desirability of outcome ranking analysis to investigate the OUTCOMEREA database.

Authors:  Stéphanie Pons; Jean-François Timsit; Stéphane Ruckly; Carole Schwebel; Laurent Papazian; Elie Azoulay; Jean Reignier; Lara Zafrani
Journal:  Intensive Care Med       Date:  2019-03-14       Impact factor: 17.440

2.  Interpreting desirability of outcome ranking (DOOR) analyses in observational studies in infectious diseases: caution still needed.

Authors:  Daniele Roberto Giacobbe; Alessio Signori
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-17       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.